Biomea Fusion (BMEA) Assets Average (2021 - 2026)
Biomea Fusion (BMEA) posted Assets Average of $52.5 million for Q1 2026, down 7.74% sequentially from $56.9 million in Q4 2025, and down 22.25% YoY from $67.5 million in Q1 2025.
Biomea Fusion (BMEA) Assets Average (2021 - 2026) Analysis & Trends
Biomea Fusion has reported Assets Average for 6 years, with the latest figure at $52.5 million in Q1 2026.
- Quarterly Assets Average fell 22.25% year-over-year to $52.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.5 million (down 22.25% YoY) and the FY2025 annual result came in at $69.3 million, down 50.51% from the prior year.
- Assets Average slipped to $52.5 million in Q1 2026 per BMEA's latest filing, from $56.9 million in the prior quarter.
- Over five years, Assets Average peaked at $236.9 million in Q3 2023 and troughed at $52.5 million in Q1 2026.
- A 5-year average of $132.4 million and a median of $137.2 million in 2022 frame the typical range for Assets Average.
- The sharpest annual moves came in 2022 and 2025: Assets Average soared 194.58% in 2022, then plunged 63.36% in 2025.
- Over 5 years, Assets Average stood at $137.2 million in 2022, then surged by 54.91% to $212.5 million in 2023, then tumbled by 55.21% to $95.2 million in 2024, then slumped by 40.24% to $56.9 million in 2025, then fell by 7.74% to $52.5 million in 2026.
- According to Business Quant data, Assets Average over the past three periods registered $52.5 million, $56.9 million, and $64.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Biomea Fusion | 97.69 Mn | 97.69 Mn | - | 41.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 41.63 Mn |
| Mar 31, 2026 | 52.48 Mn |
| Dec 31, 2025 | 56.88 Mn |
| Sep 30, 2025 | 64.18 Mn |
| Jun 30, 2025 | 64.11 Mn |
| Mar 31, 2025 | 67.50 Mn |
| Dec 31, 2024 | 95.18 Mn |
| Sep 30, 2024 | 123.29 Mn |
| Jun 30, 2024 | 152.33 Mn |
| Mar 31, 2024 | 184.21 Mn |
| Dec 31, 2023 | 212.51 Mn |
| Sep 30, 2023 | 236.88 Mn |
| Jun 30, 2023 | 180.66 Mn |
| Mar 31, 2023 | 120.97 Mn |
| Dec 31, 2022 | 137.18 Mn |
| Sep 30, 2022 | 153.39 Mn |
| Jun 30, 2022 | 168.30 Mn |
| Mar 31, 2022 | 180.28 Mn |
| Dec 31, 2021 | 192.55 Mn |
| Sep 30, 2021 | 204.47 Mn |